Inhibition of Hsp90: A new strategy for inhibiting protein kinases

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1697, Issue 1-2, 2004, Pages 233-242

  Sreedhar, Amere Subbarao ^a,b   Soti, Csaba ^a   Csermely, Péter ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

17 allylamino 17 demethoxy geldanamycin; 17AAG; Cdk; Chaperone; Cisplatin; CK II; CK refers to the old name of protein kinase CK II, casein kinase; Cyclin dependent kinase; EGF; Geldanamycin; Heat shock protein; Hsp90; Protein kinase inhibitor

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIBODY; CHAPERONE; CISPLATIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; NOVOBIOCIN; OXIDIZING AGENT; PACLITAXEL; PROTEIN KINASE INHIBITOR; PROTEIN SERINE KINASE; PROTEIN TYROSINE KINASE; PURINE ANTAGONIST; RADICICOL; THREONINE;

BINDING AFFINITY; CELL ACTIVITY; CELL STRUCTURE; CONFERENCE PAPER; CYTOLYSIS; ENZYME INHIBITION; HOMEOSTASIS; HYPOXIA; MOLECULAR MODEL; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOSKELETON; ENZYME INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; OXIDATIVE STRESS; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EUKARYOTA;

EID: 1542328907     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2003.11.027     Document Type: Conference Paper

References (132)

1. Bukau B., Horwich A.L. The Hsp70 and Hsp60 chaperone machines. Cell. 92:1998;351-366.
2. Hartl F.U. Molecular chaperones in cellular protein folding. Nature. 381:1996;571-579.
3. Hartl F.U., Hayer-Hartl M.K. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science. 295:2002;1852-1858.
4. Neupert W. Protein import into mitochondria. Annu. Rev. Biochem. 66:1997;863-917.
5. Argon Y., Simen B.B. GRP94, an ER chaperone with protein and peptide binding properties. Semin. Cell Dev. Biol. 10:1999;495-505.
6. Nicchitta C.V. A platform for compartmentalized protein synthesis: protein translation and translocation in the ER. Curr. Opin. Cell Biol. 14:2002;412-416.
7. Srivastava P.K., Menoret A., Basu S., Binder R.J., McQuade K.L. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity. 8:1998;657-665.
8. Jaattela M. Programmed cell death: many ways for cells to die decently. Ann. Med. 34:2002;480-488.
9. Jaattela M. Escaping cell death: survival proteins in cancer. Exp. Cell Res. 248:1999;30-43.
10. Martin K.J., Kritzman B.M., Price L.M., Koh B., Kwan C.P., Zhang X., Mackay A., O'Hare M.J., Kaelin C.M., Mutter G.L., Pardee A.B., Sager R. Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Res. 60:2000;2232-2238.
11. Conroy S.E., Latchman D. Do heat shock proteins have a role in breast cancer? Br. J. Cancer. 74:1996;717-721.
12. Kawanishi K., Shiozaki H., Doki Y., Sakita I., Inoue M., Yano M., Tsujinaka T., Shamma A., Monden M. Prognostic significance of heat shock proteins 27 and 70 in patients with squamous cell carcinoma of the esophagus. Cancer. 85:1999;1649-1657.
13. Jameel A., Skilton R.A., Campbell T.A., Chander S.K., Coombers R.C., Luqmani Y.A. Clinical and biological significance of HSP89 alpha in human breast cancer. Int. J. Cancer. 50:1992;409-415.
14. Ferrarini M., Heltai S., Zocchi M.R., Rugarli C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int. J. Cancer. 16:1992;613-619.
15. Lebeau J., Le Cholony C., Prosperi M.T., Goubin G. Constitutive overexpression of a 89 kDa heat shock protein gene in the HBL100 human mammary cell line converted to a tumorigenic phenotype by the EJ/T24 Harvey-ras oncogene. Oncogene. 6:1991;1125-1132.
16. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J., Wolozin B. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19:1999;5782-5791.
17. Carmichael J., Chatellier J., Woolfson A., Milstein C., Fersht A.R., Rubinsztein D.C. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 97:2000;9701-9705.
18. Warrick J.M., Chan H.Y., Gray-Board G.L., Chai Y., Paulson H.L., Bonini N.M. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet. 23:1999;425-428.
19. Sittler A., Lurz R., Lueder G., Priller J., Lehrach H., Hayer-Hartl M.K., Hartl F.U., Wanker E.E. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 10:2001;1307-1315.
20. Dou F., Netzer W.J., Tanemura F., Hart F.U., Takashima A., Gouras G.K., Greengard P., Xu H. Chaperones increase association of tau protein with microtubules. Proc. Natl. Acad. Sci. U. S. A. 100:2003;721-726.
21. Craig E.A., Weissman J.S., Horwich A.L. Heat shock proteins and molecular chaperones: mediators of protein conformation and turnover in the cell. Cell. 78:1993;365-372.
22. Johnson J.L., Craig E.A. Protein folding in vivo: unraveling complex pathways. Cell. 90:1997;201-204.
23. Pratt W.B., Toft D.O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. 228:2003;111-133.
24. Nollen E.A.A., Morimoto R.I. Chaperoning signaling pathways: molecular chaperones as stress-sensing 'heat shock' proteins. J. Cell. Sci. 115:2002;2809-2816.
25. Whitesell L., Mimnaugh E.G., De Costa B., Myers C.E., Neckers L.M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. U. S. A. 91:1994;8324-8328.
26. Neckers L., Schulte T.W., Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest. New Drugs. 17:1999;361-373.
27. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8:2002;S55-S61.
28. Csermely P., Schnaider T., Soti Cs., Prohaszka Z., Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther. 79:1998;129-168.
29. Buchner J. Hsp90 & Co.-a holding for folding. Trends Biochem. Sci. 24:1999;136-141.
30. Young J., Schneider C., Hartl F.U. In vitro evidence that hsp90 contains two independent chaperone sites. FEBS Lett. 418:1997;139-143.
31. Radanyi C., Renoir J.M., Sabbah M., Baulieu E.E. Chick heat-shock protein of Mr=90,000, free or released from progesterone receptor, is in a dimeric form. J. Biol. Chem. 264:1989;2568-2573.
32. Minami Y., Kawasaki H., Miyata Y., Suzuki K., Yahara I. Analysis of native forms and isoform compositions of the mouse 90-kDa heat shock protein, HSP90. J. Biol. Chem. 266:1991;10099-10103.
33. Perdew G.H., Hord N., Hollenback C.E., Welsh M.J. Localization and characterization of the 86- and 84-kDa heat shock proteins in Hepa 1c1c7 cells. Exp. Cell Res. 209:1993;350-356.
34. Garnier C., Lafitte D., Jorgensen T.J., Jensen O.N., Briand C., Peyrot V. Phosphorylation and oligomerization states of native pig brain HSP90 studied by mass spectrometry. Eur. J. Biochem. 268:2001;2402-2407.
35. Nemoto T., Sato N. Oligomeric forms of the 90-kDa heat shock protein. Biochem. J. 330:1998;989-995.
36. Iannotti A.M., Rabideau D.A., Dougherty J.J. Characterization of purified avian 90,000-Da heat shock protein. Arch. Biochem. Biophys. 264:1988;54-60.
37. Pearl L.H., Prodromou C. Structure, function, and mechanism of the Hsp90 molecular chaperone. Adv. Protein Chem. 59:2001;157-186.
38. Marcu M.G., Chadli A., Bouhouche I., Catelli M.G., Neckers L.M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 275:2000;37181-37186.
39. Soti Cs., Racz A., Csermely P. A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J. Biol. Chem. 277:2002;7066-7075.
40. Garnier C., Lafitte D., Tsvetkov P.O., Barbier P., Leclerc-Devin J., Millot J.M., Briand C., Makarov A.A., Catelli M.G., Peyrot V. Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain. J. Biol. Chem. 277:2002;12208-12214.
41. Freeman B.C., Morimoto R.I. The human cytosolic molecular chaperones hsp90, hsp70 (hsc70) and hdj-1 have distinct roles in recognition of a non-native protein and protein refolding. EMBO J. 15:1996;2969-2979.
42. Scheibel T., Buchner J. The Hsp90 complex-a super-chaperone machine as a novel drug target. Biochem. Pharmacol. 56:1998;675-682.
43. Cheung J., Smith D.F. Molecular chaperone interactions with steroid receptors: an update. Mol. Endocrinol. 14:2000;939-946.
44. Dittmar K.D., Demady D.R., Stancato L.F., Krishna P., Pratt W.B. Folding of the glucocorticoid receptor by the heat shock protein (hsp) 90-based chaperone machinery. The role of p23 is to stabilize receptor.hsp90 heterocomplexes formed by hsp90.p60.hsp70. J. Biol. Chem. 272:1997;21213-21220.
45. Chen S., Smith D.F. Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery. J. Biol. Chem. 273:1998;35194-35200.
46. Czar M.J., Galiganiana M.D., Silverstein A.M., Pratt W.B. Geldanamycin, a heat shock protein 90-binding benzoquinone ansamycin, inhibits steroid-dependent translocation of the glucocorticoid receptor from the cytoplasm to the nucleus. Biochemistry. 36:1997;7776-7785.
47. Pratt W.B., Silverstein A.M., Galigniana M.D. A model for the cytoplasmic trafficking of signalling proteins involving the hsp90-binding immunophilins and p50cdc37. Cell Signal. 11:1999;839-851.
48. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev., Mol. Cell Biol. 2:2001;127-137.
49. Nagy P., Jenei A., Kirsch A.K., Szollosi J., Damjanovich S., Jovin T.M. Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy. J. Cell. Sci. 112:1999;1733-1741.
50. Xu W., Mimnaugh E.G., Kim J.S., Trepel J.B., Neckers L.M. Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2. Cell Stress Chaperones. 7:2002;91-96.
51. Xu Y., Lindquist S. Heat-shock protein hsp90 governs the activity of pp60v-src kinase. Proc. Natl. Acad. Sci. U. S. A. 90:1993;7074-7078.
52. An W.G., Schulte T.W., Neckers L.M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 11:2000;355-360.
53. Gorre M.E., Ellwood-Yen K., Chiosis G., Rosen N., Sawyers C.L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 100:2002;3041-3044.
54. Munoz M.J., Bejarano E.R., Daga R.R., Jimenez J. The identification of Wos2, a p23 homologue that interacts with Wee1 and Cdc2 in the mitotic control of fission yeasts. Genetics. 153:1999;1561-1572.
55. Munoz M.J., Jimenez J. Genetic interactions between Hsp90 and the Cdc2 mitotic machinery in the fission yeast Schizosaccharomyces pombe. Mol. Gen. Genet. 261:1999;242-250.
56. Aligue R., Akhavan-Niak H., Russell P. A role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90. EMBO J. 13:1994;6099-6106.
57. Goes F.S., Martin J. Hsp90 chaperone complexes are required for the activity and stability of yeast protein kinases Mik1, Wee1 and Swe1. Eur. J. Biochem. 268:2001;2281-2289.
58. To C.T., Tsao M.S. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers. Oncol. Rep. 5:1998;1013-1024.
59. Stella M.C., Comoglio P.M. HGF: a multifunctional growth factor controlling cell scattering. Int. J. Biochem. Cell Biol. 31:1999;1357-1362.
60. Maulik G., Kijima T., Ma P.C., Ghosh S.K., Lin J., Shapiro G.I., Schaefer E., Tibaldi E., Johnson B.E., Salgia R. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin. Cancer Res. 8:2002;620-627.
61. Schulte T.W., Blagosklonny M.V., Ingui C., Neckers L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J. Biol. Chem. 270:1995;24585-24588.
62. Miyata Y., Yahara I. The 90-kDa heat shock protein, HSP90, binds and protects casein kinase II from self-aggregation and enhances its kinase activity. J. Biol. Chem. 267:1992;7042-7047.
63. Matts R.L., Hurst R. Evidence for the association of the heme-regulated eIF-2 alpha kinase with the 90-kDa heat shock protein in rabbit reticulocyte lysate in situ. J. Biol. Chem. 264:1989;15542-15547.
64. Sato S., Fugita T., Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. U. S. A. 97:2000;10832-10837.
65. Stepanova L., Leng X., Parker S.B., Harper J.W. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev. 10:1996;1491-1502.
66. Mahony D., Parry D.A., Lees E. Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells. Oncogene. 16:1998;603-611.
67. Napolitano G., Majello B., Lania L. Role of cyclinT/Cdk9 complex in basal and regulated transcription. Int. J. Oncol. 21:2002;171-177.
68. O'Keeffe B., Fong Y., Chen D., Zhou S., Zhou Q. Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription. J. Biol. Chem. 275:2000;279-287.
69. Minet E., Mottet D., Michel G., Roland I., Raes M., Remacle J., Michiels C. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett. 460:1999;251-256.
70. Maloney A., Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2:2002;3-24.
71. BeBoer C., Dietz A. The description and antibiotic production of Streptomyces hygroscopicus var, Geldanus. J. Antibiot. (Tokyo). 29:1976;1182-1188.
72. Whitesell L., Shifrin S.D., Schwab G., Neckers L. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res. 52:1992;1721-1728.
73. Schulte T.W., An W.G., Neckers L.M. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem. Biophys. Res. Commun. 239:1997;655-659.
74. Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., Pavletich N.P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell. 89:1997;239-250.
75. Prodromou C., Roe S.M., Piper P.W., Pearl L.H. A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone. Nat. Struct. Biol. 4:1997;477-482.
76. Chavany C., Mimnaugh E., Miller P., Bitton R., Nguyen P., Trepel J., Whitesell L., Schnur R., Moyer J., Neckers L. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J. Biol. Chem. 271:1996;4974-4977.
77. Supko J.G., Hickman R.L., Grever M.R., Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 36:1995;305-315.
78. Schulte T.W., Neckers L.M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 42:1998;273-279.
79. Kelland L.R., Sharp S.Y., Rogers P.M., Myers T.G., Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. 91:1999;1940-1949.
80. Brunton V.G., Steele G., Lewis A.D., Workman P. Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT-diaphorase. Cancer Chemother. Pharmacol. 41:1998;417-422.
81. Chiosis G., Huezo H., Rosen N., Mimnaugh E., Whitesell L., Neckers L. 17AAG: low target binding affinity and potent cell activity-finding an explanation. Mol. Canc. Therap. 2:2003;123-129.
82. Workman P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol. Canc. Therap. 2:2003;131-138.
83. Egorin M.J., Rosen D.M., Wolff J.H., Callery P.S., Musser S.M., Eiseman J.L. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res. 58:1998;2385-2396.
84. Kuduk S.D., Harris T.C., Zheng F.F., Sepp-Lorenzino L., Ouerfelli Q., Rosen N., Danishefsky S.J. Synthesis and evaluation of geldanamycin- testosterone hybrids. Bioorg. Med. Chem. Lett. 10:2000;1303-1306.
85. Kuduk S.D., Zheng F.F., Sepp-Lorenzino L., Rosen N., Danishefsky S.J. Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg. Med. Chem. Lett. 9:1999;1233-1238.
86. Chiosis G., Rosen N., Sepp-Lorenzino L. LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg. Med. Chem. Lett. 11:2001;909-913.
87. Van den Berghe T., Kalai M., Van Loo G., Declercq W., Vandenabeele P. Disruption of HSP90 function reverts tumor necrosis factor-induced necrosis to apoptosis. J. Biol. Chem. 278:2003;5622-5629.
88. Hostein I., Robertson D., DiStefano F., Workman P., Clarke P.A. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 61:2001;4003-4009.
89. Kwon H.J., Yoshida M., Fukui Y., Horinouchi S., Beppu T. Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res. 52:1992;6926-6930.
90. Zhao J.F., Nakano H., Sharma S. Suppression of RAS and MOS transformation by radicicol. Oncogene. 11:1995;161-173.
91. Schulte T.W., Akinaga S., Soga S., Sullivan W., Stensgard B., Toft D.O., Neckers L.M. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones. 3:1998;100-108.
92. Asher G., Lotem J., Sachs L., Kahana C., Shaul Y. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc. Natl. Acad. Sci. U. S. A. 99:2002;13125-13130.
93. Vogen S., Gidalevitz T., Biswas C., Simen B.B., Stein E., Gulmen F., Argon Y. Radicicol-sensitive peptide binding to the N-terminal portion of GRP94. J. Biol. Chem. 277:2002;40742-40750.
94. Agatsuma T., Ogawa H., Akasaka K., Asai A., Yamashita Y., Mizukami T., Akinaga S., Saitoh Y. Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities. Bioorg. Med. Chem. 10:2002;3445-3454.
95. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42:1999;260-266.
96. Hur E., Kim H.H., Choi S.M., Kim J.H., Yim S., Kwon H.J., Choi Y., Kim D.K., Lee M.O., Park H. Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol. Pharmacol. 62:2002;975-982.
97. Fuertes M.A., Castilla J., Alonso C., Perez J.M. Novel concepts in the development of platinum antitumor drugs. Curr. Med. Chem. Anti-Cancer Agents. 2:2002;539-551.
98. Wong E., Giandomenico C.M. Current status of platinum-based antitumor drugs. Chem. Rev. 99:1999;2451-2466.
99. Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99:1999;2467-2498.
100. Speelmans G., Staffhorst R.W.H.M., Versluis K., Reedijk J., de Kruijff B. Cisplatin complexes with phosphatidylserine in membranes. Biochemistry. 36:1997;10545-10550.
101. Itoh H., Ogura M., Komatsuda A., Wakui H., Miura A.B., Tashima Y. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. Biochem. J. 343:1999;697-703.
102. Chiosis G., Timaul M.N., Lucas B., Munster P.N., Zheng F.F., Sepp-Lorenzino L., Rosen N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 8:2001;289-299.
103. Chiosis G., Lucas B., Shtil A., Huezo H., Rosen N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem. 10:2002;3555-3564.
104. Wani M.C., Taylor H.L., Wall M.E., Coggon P., McPhail A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93:1971;2325-2327.
105. Schiff P.B., Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. U. S. A. 77:1980;1561-1565.
106. Byrd C.A., Bornmann W., Erdjument-Bromage H., Tempst P., Pavletich N., Rosen N., Nathan C.F., Ding A. Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide. Proc. Natl. Acad. Sci. U. S. A. 96:1999;5645-5650.
107. Torres K., Horwitz S.B. Mechanisms of taxol-induced cell death are concentration dependent. Cancer Res. 58:1998;3620-3626.
108. Munster P.N., Srethapakdi M., Moasser M.M., Rosen N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res. 61:2001;2945-2952.
109. Lopez-Maderuelo M.D., Fernandez-Renart M., Moratilla C., Renart J. Opposite effects of the Hsp90 inhibitor Geldanamycin: induction of apoptosis in PC12, and differentiation in N2A cells. FEBS Lett. 490:2001;23-27.
110. Nimmanapalli R., O'Bryan E., Kuhn D., Yamaguchi H., Wang H.G., Bhalla K.N. Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-xL, and Bax downstream of 17-AAG-mediated downregulation of Akt, Raf-1 and Src kinases. Blood. 102:2003;269-275.
111. Nimmanapalli R., O'Bryan E., Bhalla K.N. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 61:2001;1799-1804.
112. Clark P.A., Hostein I., Banerji U., Stefano F.D., Maloney A., Walton M., Judson I., Workman P. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17- demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene. 19:2000;4125-4133.
113. Stretthapakdi M., Liu F., Tavorath R., Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res. 60:2000;3940-3946.
114. Blagosklonny M.V., Fojo T., Bhalla K.N., Kim J.S., Trepel J.B., Figg W.D., Rivera Y., Neckers L.M. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia. 15:2001;1537-1543.
115. Munster P.N., Basso A., Solit D., Norton L., Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin. Cancer Res. 7:2001;2155-2158.
116. Sausville E.A. Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Munster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res. 7:2001;2228-2236.
117. Graf P.C., Jakob U. Redox-regulated molecular chaperones. Cell Mol. Life Sci. 59:2002;1624-1631.
118. Ahn S.G., Thiele D.J. Redox regulation of mammalian heat shock factor 1 is essential for Hsp gene activation and protection from stress. Genes Dev. 17:2003;516-528.
119. Nardai G., Sass B., Eber J., Orosz G., Csermely P. Reactive cysteines of the 90-kDa heat shock protein, Hsp90. Arch. Biochem. Biophys. 384:2000;59-67.
120. Liang P., MacRae T.H. Molecular chaperones and the cytoskeleton. J. Cell Sci. 110:1997;1431-1440.
121. Sussman M.A. Cellular indigestion: chaperones head to the cytoskeleton. J. Mol. Cell. Cardiol. 34:2002;83-85.
122. Csermely P. A nonconventional role of molecular chaperones: involvement in the cytoarchitecture. News Physiol. Sci. 16:2001;123-126.
123. Pai K.S., Mahajan V.B., Lau A., Cunningham D.D. Thrombin receptor signaling to cytoskeleton requires Hsp90. J. Biol. Chem. 276:2001;32642-32647.
124. Pató B., Mihály K., Csermely P. Chaperones and cytoarchitecture: geldanamycin induces an accelerated efflux of cytoplasmic proteins from detergent-treated cells. Eur. J. Biochem. 268:2001;S107.
125. Sreedhar A.S., Mihály K., Pató B., Schnaider T., Steták A., Kis-Petik K., Fidy J., Simonics T., Maráz A., Csermely P. Hsp90 inhibition accelerates cell lysis: anti-Hsp90 ribozyme reveals a complex mechanism of Hsp90 inhibitors involving both superoxide- and Hsp90-dependent events. J. Biol. Chem. 278:2003;35231-35240.
126. Dikalov S., Landmesser U., Harrison D.G. Geldanamycin leads to superoxide formation by enzymatic and non-enzymatic redox cycling. Implications for studies of Hsp90 and endothelial cell nitric-oxide synthase. J. Biol. Chem. 277:2002;25480-25485.
127. Benchekroun N.M., Myers C.E., Sinha B.K. Free radical formation by ansamycin benzoquinone in human breast tumor cells: implications for cytotoxicity and resistance. Free Radic. Biol. Med. 17:1994;191-200.
128. Shi Y., Barker J.E., Zhang C., Tweddell J.S., Su J., Pritchard K.A. Jr. Chronic hypoxia increases endothelial nitric oxide synthase generation of nitric oxide by increasing heat shock protein 90 association and serine phosphorylation. Clin. Res. 91:2002;300-306.
129. Suttitanamongkol S., Gear A.R., Polnowska-Grabowska R. Geldanamycin disrupts platelet-membrane structure, leading to membrane permeabilization and inhibition of platelet aggregation. Biochem. J. 345:2000;307-314.
130. Tanaka Y., Kamei K., Otoguro K., Omura S.J. Heme-dependent radical generation: possible involvement in antimalarial action of non-peroxide microbial metabolites, nanaomycin A and radicicol. J. Antibiot. (Tokyo). 52:1999;880-888.
131. Boudeau J., Deak M., Lawlor M.A., Morrice N.A., Alessi D.R. Heat shock protein 90 and Cdc37 interact with LKB1 and regulate its stability. Biochem. J. 370:2003;849-857.
132. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.